首页> 美国卫生研究院文献>Stem Cell Research Therapy >Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34+ cells using the auto-erasable Sendai virus vector
【2h】

Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34+ cells using the auto-erasable Sendai virus vector

机译:使用可自动擦除的仙台病毒载体从患者非动员的外周血来源的CD34 +细胞中产生稳定高效的hiPSC

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundDisease modeling with patient-derived induced pluripotent stem cells (iPSCs) is a powerful tool for elucidating the mechanisms underlying disease pathogenesis and developing safe and effective treatments. Patient peripheral blood (PB) cells are used for iPSC generation in many cases since they can be collected with minimum invasiveness. To derive iPSCs that lack immunoreceptor gene rearrangements, hematopoietic stem and progenitor cells (HSPCs) are often targeted as the reprogramming source. However, the current protocols generally require HSPC mobilization and/or ex vivo expansion owing to their sparsity at the steady state and low reprogramming efficiencies, making the overall procedure costly, laborious, and time-consuming.
机译:背景用患者来源的诱导多能干细胞(iPSC)进行疾病建模是阐明疾病发病机理和开发安全有效治疗方法的强大工具。在许多情况下,患者外周血(PB)细胞可用于iPSC生成,因为可以用最小的侵入性收集它们。为了获得缺乏免疫受体基因重排的iPSC,通常会将造血干细胞和祖细胞(HSPC)作为重编程来源。然而,当前的方案由于其在稳态的稀疏性和低的重新编程效率而通常需要动员HSPC和/或离体扩展,这使得整个过程昂贵,费力且耗时。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号